The Epidermolysis Bullosa Market is estimated to be valued at US$ 3813.38 Mn in 2023 and is expected to exhibit a CAGR of 11% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Epidermolysis bullosa (EB) refers to a group of rare genetic disorders that cause easy blistering of the skin and mucous membranes from minor friction or trauma. There are three main types of EB - simplex, dystrophic and junctional. It is caused by one or more mutations in any of at least 18 different genes that help maintain the integrity of the skin. The treatment options for EB focuses on wound and scar management, pain control, careful protection of skin, nutritional support and physiotherapy. Advancement in gene and cell therapies have opened new opportunities for EB treatment.
Market key trends:
The growing research and development activities for EB therapies such as gene and cell therapies is expected to drive the market growth over the forecast period. For instance, in October 2019, RegeneRx announced positive results from clinical trials of RGN-137 for EB. In 2021, Castle Creek Pharmaceuticals started phase 1/2 clinical trial of CCP-020, a genetically modified autologous keratinocyte therapy for the treatment of EB. Amryt Pharma’s LOTION for EB wounds is under phase 3 trials. Advances and success in clinical trials of gene and cell therapies holds potential to transform the treatment of EB. Moreover, increasing prevalence of genetic disorders along with rising awareness levels regarding EB and availability of treatment options are some other factors expected to support market growth during the forecast period.
Porter’s Analysis
Threat of new entrants: The threat of new entrants is moderate as high capital investment is required to enter the Epidermolysis Bullosa Market. The market already has major established players making it difficult for new players.
Bargaining power of buyers: Buyers have moderate bargaining power as there are limited customized treatment options available for the rare disease of epidermolysis bullosa.
Bargaining power of suppliers: Suppliers have moderate bargaining power due to the fragmented nature of suppliers in the market.
Threat of new substitutes: There is low threat from substitutes as there are limited approved treatment options available and a high unmet clinical need for effective therapies.
Competitive rivalry: High as major players are focusing on R&D of novel drugs and treatments.
SWOT Analysis
Strength: Growing research and development activities for developing advanced therapies. Significant unmet clinical need for effective treatments.
Weakness: High treatment cost associated with Epidermolysis Bullosa limiting access. Complexity of disease hindering drug development process.
Opportunity: Favorable regulatory environment and fast-track approvals encouraging drug innovation. Emerging economies providing potential growth opportunities.
Threats: Risk of failure and side effects in drug development. Reimbursement issues and healthcare affordability challenges.
Key Takeaways
The Global Epidermolysis Bullosa Market Size is expected to witness high growth, exhibiting CAGR of 11% over the forecast period, due to increasing prevalence of rare skin diseases and rising awareness.
Regional analysis
North America dominated the global EB market in 2023 and is expected to continue its dominance over the forecast period, owing to high adoption of advanced treatment options and presence of key industry players in the region. Asia Pacific is poised to witness the fastest growth rate during the forecast period, driven by large patient population, increased healthcare spending, and improving access to diagnosis and care.
Key players
Key players operating in the Epidermolysis Bullosa market are Amryt Pharma, Abeona Therapeutics, Castle Creek Pharmaceuticals, RegeneRx, Krystal Biotech, RHEACELL GmbH, Holostem Terapie Avanzate, StemRim/Shionogi, and Phoenix Tissue Repair.
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian